We identified a hypoxia- and PLOD2-linked mechanism underlying DCLK1 activation and α-promoter preference, and evaluated the therapeutic significance of targeting DCLK1-L in ccRCC. This evidence concerns the gene DCLK1 and nonpapillary renal cell carcinoma.